1 min read
Add as a preferred source on GoogleIGC Pharma Reports $0.32 Million in Third-Quarter Revenue
Net loss attributable to common stockholders widened to $2.046 million from $1.821 million, while basic and diluted loss per share was 2 cents.
IGC Pharma, Inc. reported third-quarter revenue of $0.32 million and a wider net loss attributable to common stockholders.
Third-quarter revenue was $0.32 million. Net loss attributable to common stockholders widened to $2.046 million from $1.821 million. Basic and diluted net loss per share was 2 cents.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.